Niquitine Minis 4 mg de menthes de menthe est un type de produit de thérapie de remplacement de nicotine (NRT) utilisé pour aider les gens à arrêter de fumer. Le produit se présente sous la forme de petites pastilles à dissolution rapide qui contiennent 4 mg de nicotine. Lorsqu'elles sont placées dans la bouche, les pastilles libèrent de la nicotine, qui est absorbée dans la circulation sanguine par la muqueuse de la bouche. Cela peut aider à réduire les envies et les symptômes de sevrage qui se produisent lorsque quelqu'un cesse de fumer.

Comment utiliser:

Mettez une pastille dans votre bouche et laissez-la se dissoudre
Ne mâchez pas et n'avalez pas la pastille.
Utilisez jusqu'à 15 passes par jour.
Réduisez progressivement le nombre de pastilles.

Remarque: Ces images de produits présentées peuvent représenter la gamme de produits ou être à des fins d'illustration uniquement et ne peuvent pas être une représentation exacte du produit.

Nicotine polacrilex, mannitol, sodium alginate, xanthan gum, potassium bicarbonate, magnesium stearate, sucralose, and mint flavouring.

Welzo is not liable for discrepancies on the website. Check product packaging for exact information.

• GTIN: 5.01262E+12
• Manufacturer: Niquitin
• Size: 4 mg / Pack de 60
• Categories: NiquitineNizines de nicotineProduits en vente libre
• Best buy: 6 - 24 months+

United Kingdom & Rest of the World Shipping Details:
Same day dispatch for orders placed by 2pm (Orders after 2pm dispatched next working day).

Free shipping on orders over £50 to the UK.

Returns: Our products are meant to make you feel healthy and at your best. If you need to return your item, you can do so free of charge within 30 days in the same original and unopened packaging. Subject to T&C's.

Instructions for Using NiQuitin Lozenges

The appropriate lozenge strength depends on individual smoking habits. NiQuitin Minis Mint Lozenges, available in 4 mg and 1.5 mg, are intended for those who smoke over 20 cigarettes daily. Place one lozenge in the mouth and let it dissolve, moving it occasionally from one side to the other until fully dissolved, which takes about 10 minutes. Do not chew or swallow the lozenge whole. Avoid eating or drinking while the lozenge is in your mouth. Behavioral therapy and support can enhance success rates.

For Adults (18 years and older):

Abrupt Smoking Cessation:
- Aim to completely stop smoking while using NiQuitin Minis Mint Lozenges.
- Use a lozenge whenever you feel the urge to smoke.
- Typically, use 8-12 lozenges daily, with a maximum of 15.
- Continue for up to six weeks, then gradually reduce usage. Stop when down to 1-2 lozenges per day.
- To maintain a smoke-free status, use a lozenge when tempted to smoke.
- If using lozenges beyond 9 months, seek advice from a healthcare professional.

Gradual Smoking Cessation:
- For those unable or unwilling to quit abruptly.
- Use a lozenge when you have a strong urge to smoke to reduce cigarette consumption.
- The number of lozenges varies based on individual needs but should not exceed 15 per day.
- If no reduction in smoking is seen after 6 weeks, consult a healthcare professional.
- Aim for complete cessation as soon as possible. Once cigarette use is reduced to a manageable level, follow the "abrupt cessation" schedule.
- If a complete quit attempt hasn't started within 6 months, consult a healthcare professional.

Temporary Abstinence:
- Use a lozenge every 1-2 hours to manage withdrawal symptoms, not exceeding 15 lozenges per day.
- Encourage complete smoking cessation as soon as possible.
- If regular lozenge use continues 6 months after starting treatment without a quit attempt, seek additional help from a healthcare professional.

For Children and Adolescents:
- Adolescents (12-17 years) should follow the abrupt cessation schedule, limiting use to 12 weeks. If longer treatment is needed, or if unable to quit abruptly, consult a healthcare professional.
- Safety and effectiveness in children under 12 have not been evaluated. Ni

Welzo is not liable for allergen information. Always follow the directions/ingredients on the product packaging to ensure proper use.

The risks of using Nicotine Replacement Therapy (NRT) are generally much lower than the dangers of continued smoking. Patients hospitalized for heart attack, severe heart rhythm issues, or stroke who are not stable should try to quit smoking using non-drug methods. If these methods fail, NiQuitin Mint or Original Lozenges may be considered, but due to limited safety data for this group, they should only be started under medical supervision. After hospital discharge, patients can use NRT as usual.

Diabetes Mellitus: Patients with diabetes should closely monitor blood sugar levels when starting NRT, as nicotine can affect carbohydrate metabolism.

Allergic reactions: Risk of angioedema and hives.

A healthcare professional should assess risks and benefits for patients with the following conditions:

Renal and hepatic impairment: Use cautiously in patients with moderate to severe liver or severe kidney impairment, as nicotine clearance may be reduced, increasing adverse effects.

Phaeochromocytoma and uncontrolled hyperthyroidism: Use cautiously as nicotine can release catecholamines.

GI disease: Swallowed nicotine may worsen symptoms in patients with esophagitis, gastric or peptic ulcers. Use oral NRT preparations cautiously. Ulcerative stomatitis has been reported.

Danger in small children: Nicotine doses tolerated by adults and adolescents can be highly toxic and potentially fatal to small children. Keep nicotine products out of children's reach.

Stopping smoking: Quitting smoking may slow the metabolism of certain drugs, leading to increased blood levels.

Transferred dependence: Rare and less harmful than smoking dependence.

Phenylketonuria: NiQuitin Mint or Original Lozenges contain phenylalanine, which may be harmful to people with phenylketonuria.

Sodium content: Each lozenge contains 15 mg of sodium. Consider this for low-sodium diets.

KEEP ALL MEDICINES OUT OF REACH AND SIGHT OF CHILDREN. READ ALL PRODUCT PACKAGING AND LABELS BEFORE USE.